Search

Search Constraints

You searched for: Author/Creator Soria, Jean-Charles

Search Results

1. 274 Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced non-small cell lung cancer. (10th December 2020)

3. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. (November 2018)

4. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Issue 2 (February 2015)

5. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer. (November 2017)

6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Issue 9 (September 2018)

7. Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. (October 2016)

8. Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. Issue 4 (July 2018)

9. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Issue 8 (August 2015)

10. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Issue 8 (August 2015)